Semaglutide and walking capacity in people with symptomatic lower extremity artery disease and type 2 diabetes: STRIDE Japanese cohort study
The STRIDE trial demonstrated that among Japanese patients with type 2 diabetes and intermittent claudication, the addition of semaglutide to standard care improved walking capacity and lower extremity artery disease (LEAD)-related quality of life compared with placebo, consistent with the overall trial population, according to a study presented by Dr. Masato Nakamura, Toho University Ohashi Medical Center, Japan, in the Late Breaking Clinical Trials session at the 90th Annual Scientific Meeting of the Japanese Circulation Society.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations